Wednesday, July 8, 2026

Patent intelligence · US

US 7250169

Anti-tumor activity of Ea-4-peptide of pro-IGF-1

granted A61KA61K31/711A61K38/30A61P
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 1
Applicant portfolio 179
Patent details — US 7250169
Jurisdiction
US
Status
granted
Grant date
Jul 31, 2007
Expiration
Jul 26, 2027
Claims
3
CPC classes
A61K, A61K31/711, A61K38/30, A61P
View on Google Patents ↗

Quick answer

US 7250169 (Anti-tumor activity of Ea-4-peptide of pro-IGF-1) is held by UNIVERSITY OF CONNECTICUT. Status: granted. Granted Jul 31, 2007. Expires Jul 26, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
3
CPC classes
A61K, A61K31/711, A61K38/30, A61P, A61P35/00

More from UNIVERSITY OF CONNECTICUT

Related pharmaceutical patents in our USPTO index.

  1. US 12311017

    Identification of immunologically protective neo-epitopes for the treatment of cancers

    UNIVERSITY OF CONNECTICUT · Expires May 22, 2045

    granted
  2. US 12251378

    Long-acting local anesthetic formulation

    UNIVERSITY OF CONNECTICUT · Expires Mar 13, 2045

    granted
  3. US 12202822

    Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition

    SuZhou Connect Biopharmaceuticals, Inc. · Expires Jan 16, 2045

    granted
  4. US 12156879

    Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy

    UNIVERSITY OF CONNECTICUT · Expires Nov 28, 2044

    granted
  5. US 12060555

    MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis

    UNIVERSITY OF CONNECTICUT · Expires Aug 8, 2044

    granted
  6. US 12029787

    Method for generating recombinant poxviruses

    UNIVERSITY OF CONNECTICUT · Expires Jul 4, 2044

    granted
  7. US 12018255

    Compositions and methods for treating disorders of genomic imprinting

    UNIVERSITY OF CONNECTICUT · Expires Jun 20, 2044

    granted
  8. US 11952419

    Reagents and methods for treating cancer and autoimmune disease

    UNIVERSITY OF CONNECTICUT · Expires Apr 4, 2044

    granted

Frequently asked questions

What is US patent 7250169?

US 7250169 (Anti-tumor activity of Ea-4-peptide of pro-IGF-1) is held by UNIVERSITY OF CONNECTICUT. Status: granted. Granted Jul 31, 2007. Expires Jul 26, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7250169?

UNIVERSITY OF CONNECTICUT is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 179 pharmaceutical patents for this assignee.

When does US 7250169 expire?

Our index shows an expiration date of Jul 26, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.